Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. KRON
KRON logo

KRON Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
72.11M
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
-46.08M
EV/OCF(TTM)
--
P/S(TTM)
5.72
Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases. Its product candidates include KB-9558 and KB-7898. KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN, is in preclinical development for the treatment of multiple myeloma and human papillomavirus (HPV)-driven tumors. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. KB-7898 is a p300 KAT inhibitor for the treatment of Sjogren’s disease, a chronic autoimmune disease that is characterized by the production of autoantibodies, chronic inflammation and lymphocytic infiltration of the exocrine glands that lead to uncomfortable dryness symptoms, known as sicca.
Show More

Events Timeline

(ET)
2026-01-05
06:30:00
Kronos Completes Acquisition of Zyppah to Expand Sleep Apnea Market
select
2025-07-22 (ET)
2025-07-22
08:30:11
Sixteen option delistings on July 22nd
select
2025-05-01 (ET)
2025-05-01
08:33:59
Kronos Bio to be acquired by Concentra for 57c per sare in cash plus CVR
select
2025-03-18 (ET)
2025-03-18
16:09:59
Kronos Bio reports Q4 EPS (43c) vs. (43c ) last year
select
2024-11-27 (ET)
2024-11-27
06:32:51
Kronos Bio announces workforce reduction of 83% by year-end
select
2024-11-27
06:32:01
Kronos Bio CEO Norbert Bischofberger steps down, Deborah Knobelman named interim
select
2024-11-14 (ET)
2024-11-14
15:59:17
Kronos Bio provides update on review of strategic alternatives
select
2024-11-14
15:58:35
Kronos Bio to present preclinical data from p300 KAT inhibitor program
select

News

PRnewswire
7.0
2025-05-28PRnewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KRON, AXL, TASK, STRR on Behalf of Shareholders
  • Investigation of Companies: Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches related to the sales and mergers of several companies, including Kronos Bio, American Axle, TaskUs, and Star Equity Holdings.

  • Legal Support for Shareholders: The firm offers free consultations to shareholders affected by these transactions, seeking increased compensation or additional disclosures on their behalf, with no upfront legal fees required.

Globenewswire
7.0
2025-05-18Globenewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AXL, KRON, PRA, SWTX on Behalf of Shareholders
  • Investigation of Companies: Halper Sadeh LLC is investigating potential securities law violations and breaches of fiduciary duties related to mergers and sales involving American Axle, Kronos Bio, ProAssurance, and SpringWorks Therapeutics.

  • Shareholder Rights: The firm encourages shareholders from these companies to contact them for legal rights and options regarding the proposed transactions, with services offered on a contingent fee basis.

Globenewswire
7.0
2025-05-15Globenewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders
  • Investigation of Companies: Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sales and mergers of several companies, including Regulus Therapeutics, Kronos Bio, Longevity Health Holdings, and Southern States Bancshares.

  • Shareholder Rights: The law firm encourages shareholders from these companies to contact them for information on their legal rights and options regarding the proposed transactions, emphasizing that they operate on a contingent fee basis.

Globenewswire
8.5
2025-05-15Globenewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (Nasdaq - KRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (Nasdaq - XAGE), Southern States Bancshares, Inc. (Nasdaq - SSBK)
  • Investigation Announcements: Brodsky & Smith is investigating potential breaches of fiduciary duties by the boards of several companies, including Regulus Therapeutics, Kronos Bio, Longevity Health Holdings, and Southern States Bancshares, regarding their merger agreements and whether shareholders are receiving fair value for their shares.

  • Merger Details: Each company mentioned has entered into merger agreements with specified cash payments or stock exchanges, raising concerns about the fairness of these transactions and the protection of shareholder interests.

PRnewswire
7.0
2025-05-06PRnewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders
  • Investigation into Companies: Halper Sadeh LLC is investigating several companies, including Regulus Therapeutics, Kronos Bio, Pacific Premier Bancorp, and Coeptis Therapeutics, for potential violations of federal securities laws and breaches of fiduciary duties related to their proposed sales and mergers.

  • Legal Support for Shareholders: The firm offers legal assistance to shareholders seeking to understand their rights and options regarding these transactions, emphasizing that they operate on a contingent fee basis with no upfront costs for clients.

Globenewswire
7.0
2025-05-03Globenewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DNB, COLB, KRON on Behalf of Shareholders
  • Investigation of Companies: Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sales and mergers of Dun & Bradstreet Holdings, Columbia Banking System, and Kronos Bio.

  • Legal Support for Shareholders: The firm offers free consultations to shareholders affected by these transactions, aiming to seek increased consideration or other benefits on their behalf without upfront legal fees.

Valuation Metrics

The current forward P/E ratio for Kronos Bio Inc (KRON.O) is -0.71, compared to its 5-year average forward P/E of -2.14. For a more detailed relative valuation and DCF analysis to assess Kronos Bio Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.14
Current PE
-0.71
Overvalued PE
0.27
Undervalued PE
-4.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.42
Current EV/EBITDA
0.62
Overvalued EV/EBITDA
1.72
Undervalued EV/EBITDA
-2.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
11.92
Current PS
14.06
Overvalued PS
28.92
Undervalued PS
-5.08

Financials

AI Analysis
Annual
Quarterly

Whales Holding KRON

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Kronos Bio Inc (KRON) stock price today?

The current price of KRON is 0 USD — it has increased 0

What is Kronos Bio Inc (KRON)'s business?

Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases. Its product candidates include KB-9558 and KB-7898. KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN, is in preclinical development for the treatment of multiple myeloma and human papillomavirus (HPV)-driven tumors. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. KB-7898 is a p300 KAT inhibitor for the treatment of Sjogren’s disease, a chronic autoimmune disease that is characterized by the production of autoantibodies, chronic inflammation and lymphocytic infiltration of the exocrine glands that lead to uncomfortable dryness symptoms, known as sicca.

What is the price predicton of KRON Stock?

Wall Street analysts forecast KRON stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRON is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Kronos Bio Inc (KRON)'s revenue for the last quarter?

Kronos Bio Inc revenue for the last quarter amounts to 1.86M USD, decreased -26.03

What is Kronos Bio Inc (KRON)'s earnings per share (EPS) for the last quarter?

Kronos Bio Inc. EPS for the last quarter amounts to -0.14 USD, decreased -72.00

How many employees does Kronos Bio Inc (KRON). have?

Kronos Bio Inc (KRON) has 10 emplpoyees as of April 04 2026.

What is Kronos Bio Inc (KRON) market cap?

Today KRON has the market capitalization of 72.11M USD.